across solid tumors with high microsatellite instability status as well as for Keytruda combined with Eisai and Merck’s ...

Median overall survival (OS) increased from 19.3 months with upfront immune checkpoint inhibition (ICI) to 41.3 months when a ...

According to data from the phase 3 double-blinded, active-controlled, multicenter LEAP-012 trial (NCT04246177), lenvatinib (Lenvima) with pembrolizumab (Keytruda) and transarterial chemoembolization ...

The company’s MI Cancer Seek is approved as a companion diagnostic for multiple cancer therapies, including MSD’s Keytruda, ...

The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

Credit: SewCreamStudio / Shutterstock. Moderna and MSD have initiated a Phase III clinical study to evaluate mRNA-4157 (V940), an investigational individualised neoantigen therapy, in combination with ...

Analysts forecast 'Sales- Oncology- Keytruda' to reach $7.38 billion ... analysts suggests that 'Sales- Oncology- Alliance revenue- Lenvima' will likely reach $275.08 million.

in combination with Keytruda, Merck’s anti-PD-1 therapy, as adjuvant treatment for patients with resectable Stage II, IIIA or IIIB non-small cell lung cancer who did not achieve a pathological ...

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, ...

In oncology drugs, Keytruda sales are likely to have been ... Alliance revenues from Lenvima may have also boosted oncology sales. Sales of Welireg are likely to have been driven by the launch ...